Abstract:Kinase drug selectivity is the ground challenge in cancer research. Due to the structurally similar kinase drug pockets, off-target inhibitor toxicity has been a major cause for clinical trial failures. The pockets are similar but not identical. Here, we describe a transformation invariant protocol to identify distinct geometric features in the drug pocket that can distinguish one kinase from all others. We integrate available experimental structures with the artificial intelligence-based structural kinome, performing a kinome-wide structural bioinformatic analysis to establish the structural principles of kinase drug selectivity. We generate the structural landscape from the experimental kinase-ligand complexes and propose a binary network that encapsulates the information. The results show that all kinases contain binary units that are shared by less than seven other kinases in the kinome. 331 kinases contain unique binary units that may distinguish them from all others. The structural features encoded by these binary units in the network represent the inhibitor-accessible geometric space that may capture the kinome-wide selectivity. Our proposed binary network with the unsupervised clustering can serve as a general structural bioinformatic protocol for extracting the distinguishing structural features for any protein from their families. We apply the binary network to epidermal growth factor receptor tyrosine kinase inhibitor selectivity by targeting the gate area and the AKT1 serine/threonine kinase selectivity by binding to the αC-helix region and the allosteric pocket. Finally, we develop the cross-platform software, KDS (Kinase Drug Selectivity), for customized visualization and analysis of the binary networks in the human kinome (https://github.com/CBIIT/KDS).

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Using the Structural Kinome to Systematize Kinase Drug Discovery

[Progress in the Design of Selective ATP-competitive Kinase Inhibitors].

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Targeting cancer with small molecule kinase inhibitors

Strategy toward Kinase-Selective Drug Discovery

Kinase Inhibition via Small Molecule‐Induced Intramolecular Protein Cross‐Linking

Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting

Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine

Discovery of novel small-molecule Src kinase inhibitors via a kinase-focused druglikeness rule and structure-based virtual screening

Docking of Protein Kinase B Inhibitors: Implications in the Structure-Based Optimization of A Novel Scaffold

Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

A Road Map to Evaluate the Proteome-Wide Selectivity of Covalent Kinase Inhibitors.

Remarkably Stereospecific Utilization of ATP Α,β-Halomethylene Analogues by Protein Kinases.

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

2-Ethynylbenzaldehyde-based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases.